InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer

• Thomas Taapken, Ph.D. appointed Chief Financial Officer
  
• Jordan Zwick promoted to Chief Strategy Officer

JENA, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced two management appointments. Effective October 1, 2020, Thomas Taapken, Ph.D. will join InflaRx as Chief Financial Officer. Jordan Zwick has been promoted to Chief Strategy Officer, effective immediately.

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “I am delighted to welcome Thomas to InflaRx. He brings extensive senior management expertise in the public biopharmaceutical sector, including at companies with marketed products, and is an ideal fit as we advance our late-stage clinical development programs. Thomas has proven great leadership capabilities and is an excellent addition to our C-suite. I am also very pleased that Jordan has agreed to take on the newly created role of Chief Strategy Officer at the Company. Jordan has extensive experience in the U.S. biotech and pharma industry and strategic development and has a great network. He has been instrumental for various important developments in the Company and will foster our U.S. strategic footprint.”

Prof. Riedemann continued: “I would further like to take this opportunity to thank our outgoing CFO, Arnd Christ, for his contributions to InflaRx and the great team spirit and hard work he has provided throughout his 5 years in the Company. We all wish him the very best for his future endeavors.”

Thomas Taapken, Ph.D., said: “I am thrilled to join InflaRx as Chief Financial Officer at a very exciting time as the Company starts its first Phase III trial. InflaRx has made breakthrough discoveries in the area of anti-C5a therapeutics.  Their work is significantly contributing to finding cures for several chronic inflammatory diseases, as well as life-threatening diseases such as COVID-19-induced pneumonia. I believe that IFX-1 has great potential, and, based on the data available, I am convinced we will be able to develop a drug for patients with serious inflammatory diseases and high unmet medical needs. I am truly impressed with the team and the great work they are doing and look forward to helping to move InflaRx into the next stage in its development.”